Physicians practicing within the Canabo Medical Clinic network, which is owned by Aleafia, will lead the study

Marijuana leaves in a tea cup

The aim of the investigation is to use cannabis to assist in the treatment of insomnia

The Canadian cannabis company Cronos Group (NASDAQ:CRON, TSX:CRON) is teaming up with the Vancouver-based medical cannabis company Aleafia Health Inc (OTCMKTS:ALEAF) to work on a joint medical cannabis study designed to improve the treatment of insomnia and daytime sleepiness.

The study is funded in part by Peace Naturals Project Inc, a licensed producer of medical cannabis that is wholly-owned by Cronos. Physicians practicing within the Canabo Medical Clinic network, which is owned by Aleafia, will lead the investigation.

Cronos shares rose 7% to US$13.58 in Thursday’s pre-market session while Aleafia Health shares stayed flat at US$1.45.

The aim of the initiative is use cannabis to assist in the management of insomnia and the development of non-addictive, natural sleep aids.

“There is mounting evidence of the risks of prescription sleeping aids including worsening mental health and increased risk of dementia,” said Aleafia’s chief medical officer Michael Verbora in a statement.

“This study may in part point to medical cannabis as an alternative to harmful prescription drugs,” Verbora added.

Toronto-based Cronos Group is a diversified cannabis company with a presence across four continents. It operates two wholly-owned Canadian licensed producers regulated under Health Canada’s Access to Cannabis for Medical Purposes Regulations. They are Peace Naturals Project Inc and Original BC Ltd, which is based in the Okanagan Valley of British Columbia.

Aleafia, meanwhile, operates a medical cannabis clinic network in Canada under the Canabo Medical Clinic brand, which is staffed by licensed physicians.

While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds

The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

View full company profile

A geographically diversified and vertically integrated cannabis group that operates within Health Canada’s Access to Cannabis for Medical Purposes Regulations and distributes globally.

Market Cap: $2,226.75M
Latest Price: $12.55   ()
52-week H/L: $15.30 / $1.70
Sector: Pharmaceuticals